Firm’s Online Asset Evaluation Tool Goes Beyond the Spreadsheet to Give Companies a Novel Way to Manage Global Forecasting in Earliest Stages
E. Norriton, Penn. and Melrose, UK. 9.14.17. Credible forecasts create hundreds of millions of dollars of additional value for biopharma companies and investors, according to research by TGaS® Advisors, a benchmarking and advisory services firm for life sciences commercial operations. Understanding asset evaluation is considered a critical element of the drug commercialization process and a fundamental component underpinning global commercial strategy development. To enable life sciences companies to maximize both their asset development and strategic launch plans, TGaS has formed a partnership with Mirador Analytics, Ltd., a UK company with advanced global forecasting capabilities. The partnership makes asset forecasting and benchmarking available as a holistic service offering to global biopharmaceutical organizations.
Mirador Analytics has developed an advanced forecasting tool that goes well beyond the spreadsheet analysis common to the industry, according to Tim Wohlgemut, Senior Vice President, TGaS Insights. “The increasing complexity of drug development today, particularly in specialty, oncology and immunotherapy, makes it far more difficult to predict uptake and pricing on a global scale.” All aspects of drug development are under greater scrutiny, requiring a new level of credibility in forecasting, said Wohlgemut. “TGaS’ and Mirador Analytics’ combined processes and tools have ‘baked in’ many of the best practices that our research shows are vital for creating significant value through credible forecasting.”
The UK company has deep expertise in global forecasting across the life sciences, with special capabilities in the complex areas of oncology, rare diseases and immunotherapy. The firm features fully integrated services and structure across all relevant functional disciplines, including analytics, programming, strategic planning, insight, pricing, marketing, business development and Medical Affairs.
Speaking of the agreement, Jamie Blackport, Mirador Co-Founder and CEO, said, “The TGaS and Mirador Analytics partnership represents both organizations’ passion to support biopharma firms’ efforts in drug development and launch, an inherently complex and uncertain process.”
For more information, contact David Johnson, Mirador Business Development & Analytics, davidjohnson@miradoranalytics.com, or Tim Wohlgemut, TGaS Insights, Tim.Wohlgemut@tgas.com.
About TGaS® Advisors
TGaS Advisors is the leading benchmarking and advisory services firm for commercial organizations in the life sciences industry. With a roster of top 50, emerging and precommercial life sciences companies, TGaS provides robust comparative intelligence and collaborative network membership services. The team includes more than 60 experienced professionals, most with senior level experience in the life sciences and related industries. To learn more, visit www.tgas.com.
About Mirador Analytics
Mirador Analytics is a European and North American-based commercialization catalyst, fostering the drug innovation process and providing drug commercialization assessment and launch planning services to biopharma SMEs around the world. In particular, Mirador Analytics supports clinical, regulatory and commercial development decisions, with an overall viewpoint of assisting launch planning, strategic partnerships and securing investments. With an average of 17 years’ biopharma industry experience amongst the senior team members, Mirador analytics has a wealth of experience in product commercialization, forecasting and payer expertise across the US, EU and Japan. To learn more, visit www.miradoranalytics.com.
